CRISPR Therapeutics AG (CRSP) Change in Acquisitions & Divestments (2020 - 2026)

CRISPR Therapeutics AG has disclosed Change in Acquisitions & Divestments across 7 years of filings, most recently posting $192.8 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $192.8 million, up 3.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 2089.75% YoY), and the FY2025 annual result was $1.0 billion, changed N/A from the prior year.
• Change in Acquisitions & Divestments came in at $192.8 million for Q1 2026 at CRISPR Therapeutics AG, down from $300.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $419.7 million in Q3 2022 to a low of -$834.8 million in Q4 2024.
• The 5-year median for Change in Acquisitions & Divestments is $287.4 million (2023), against an average of $226.6 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 194.21% in 2022 and sank 390.43% in 2024, its largest moves.
• CRISPR Therapeutics AG's Change in Acquisitions & Divestments stood at $325.1 million in 2022, then fell by 11.57% to $287.4 million in 2023, then tumbled by 390.43% to -$834.8 million in 2024, then soared by 135.94% to $300.0 million in 2025, then slumped by 35.74% to $192.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $192.8 million (Q1 2026), $300.0 million (Q4 2025), and $214.9 million (Q3 2025), per Business Quant data.